menu
    • menu

    Company profile for Hutchmed

    NEW Drugs in Dev: 33
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capability. As of 2020, we have an in-house scientific team of over 600 professionals, and a pipeline of 10 clinical stage drug candidates in clinical studies around the world. We have also developed a profitable commercial plat...
    We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capability. As of 2020, we have an in-house scientific team of over 600 professionals, and a pipeline of 10 clinical stage drug candidates in clinical studies around the world. We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes prescription drugs and consumer health products, as well as two of our marketed novel oncology products.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    HutchmedHongKong Flag
    Country
    Country
    Hong Kong
    Address
    Address
    48th Floor, Cheung Kong Center 2 Queen's Road Central
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.hutch-med.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HUTCHMED Highlights SACHI Phase III Results in the Lancet
    HUTCHMED Highlights SACHI Phase III Results in the Lancet

    14 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-14/hutchmed-highlights-publication-of-phase-iii-sachi-results-in-the-lancet

    PHARMIWEB
    14 Jan 2026
    Share Share
    Hutchmed Heats Up Autoimmune Race With Phase 3 Win
    Hutchmed Heats Up Autoimmune Race With Phase 3 Win

    07 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/hutchmed-heats-autoimmune-race-phase-3-win-teeing-china-filing

    FIERCE BIOTECH
    07 Jan 2026
    Share Share
    HUTCHMED Starts Phase III Trial For Surufatinib And Camrelizumab
    HUTCHMED Starts Phase III Trial For Surufatinib And Camrelizumab

    04 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212410/0/en/HUTCHMED-Initiates-Phase-III-Stage-of-the-Ongoing-Trial-of-the-Combination-of-Surufatinib-and-Camrelizumab-for-Treatment-Na%C3%AFve-Pancreatic-Ductal-Adenocarcinoma.html

    GLOBENEWSWIRE
    04 Jan 2026
    Share Share
    Hutchmed's NDA Acceptance in China with Status for Savolitinib
    Hutchmed's NDA Acceptance in China with Status for Savolitinib

    30 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/30/3211274/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-with-Priority-Review-Status-for-Savolitinib-for-the-treatment-of-Gastric-Cancer-Patients-with-MET-Amplification.html

    GLOBENEWSWIRE
    30 Dec 2025
    Share Share
    Hutchmed's Fanregratinib NDA Accepted In China With Priority
    Hutchmed's Fanregratinib NDA Accepted In China With Priority

    29 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/29/3210799/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-with-Priority-Review-Status-for-Fanregratinib-in-Second-Line-Intrahepatic-Cholangiocarcinoma.html

    GLOBENEWSWIRE
    29 Dec 2025
    Share Share
    HUTCHMED Starts Global Trials For Solid Tumor Drug HMPL-A251
    HUTCHMED Starts Global Trials For Solid Tumor Drug HMPL-A251

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/17/3206674/0/en/HUTCHMED-Initiates-Global-Clinical-Development-of-ATTC-Candidate-HMPL-A251-in-Patients-with-Solid-Tumors.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search